New Guidelines Issued for Management of Gout

Two-part guidelines include approaches to hyperuricemia; therapy, prophylaxis for acute gout

TUESDAY, Oct. 2 (HealthDay News) -- Approaches for management of gout are presented in a two-part guideline issued by the American College of Rheumatology (ACR) and published online Sept. 28 in Arthritis Care & Research.

In part one, Dinesh Khanna, M.D., from the University of Michigan in Ann Arbor, and colleagues from the ACR reviewed the literature to examine the systematic non-pharmacologic and pharmacologic recommendations for management of hyperuricemia. The authors provide general health, diet, and lifestyle measures for all gout patients. A xanthine oxidase inhibitor, such as allopurinol, should be considered the first-line urate-lowering pharmacological approach to reduce urate levels to less than 6 mg/dL. The recommended initial dose should not exceed 100 mg/day and should be less for patients with moderate to severe chronic kidney disease. Screening for HLA-B*5801 should be considered for patients at high-risk of allopurinol reactions. When target urate levels are not achieved, combination therapy is recommended with one xanthine oxidase inhibitor and one uricosuric agent. For uricosuric monotherapy, probenecid is the first-choice agent.

In part two, Khanna and colleagues review management approaches for treatment and prophylaxis for acute gout attacks. They recommend initiating pharmacologic therapy within 24 hours of attack onset. Urate-lowering therapy should be continued during attacks. First-line treatment options for acute gout include use of one or a combination of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or oral colchicine. When initiating urate-lowering therapy, oral colchicine or low-dose NSAIDs should be used as anti-inflammatory prophylaxis to prevent acute gout attacks.

"Our goal is that these guidelines, along with educating gout patients in effective treatment, will improve adherence, quality of care, and management of this painful and potentially chronically debilitating condition," a coauthor said in a statement.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract - Part 1
Full Text (subscription or payment may be required)
Abstract - Part 2
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events